好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Sex and Gender Differences Influence Urinary Symptoms and Management in Multiple System Atrophy
Neuromuscular and Clinical Neurophysiology (EMG)
P8 - Poster Session 8 (11:45 AM-12:45 PM)
4-001
We sought to characterize sex and gender differences in the symptomatology, evaluation and management of urinary dysfunction in patients with MSA.
Multiple system atrophy (MSA) is characterized by urinary dysfunction, yet the influence of sex and gender on urinary symptoms and treatment is unclear. 
Patients with MSA evaluated with autonomic testing at Mayo Clinic between 1998 and 2012 were reviewed for urinary symptoms, diagnostics, and management, and stratified by sex. 
While the prevalence of urinary symptoms was similar between males and females (91.9% vs 89.1%), incontinence was more common amongst females (68.1% vs 50.6% for males, p < 0.001). Despite this, males and females were referred for urodynamic studies at similar rates (27.0% vs 27.7%). Males were more likely to have an elevated postvoid residual on urodynamic studies (72.9% vs 50.5%) which was not driven by comorbid BPH. While male and female patients were initiated on catheterization at similar rates when urodynamic studies were performed, males were more than two times more likely to be catheterized than females without urodynamic evaluation (27.3% vs 10.9%, p < 0.001). 

Urinary symptoms are common in MSA, but the presentation differs between males and females. The difference in catheterization rates may be driven by a gender disparity in referrals for PVR, which can guide treatment.  This may provide an opportunity for standardized evaluation of urinary symptoms for males and females. 
Authors/Disclosures
Elke Schipani, MD
PRESENTER 		Dr. Schipani has nothing to disclose.
Sara Hooshmand, MD (Mayo Clinic) Dr. Hooshmand has nothing to disclose.
Negin Badihian, MD Dr. Badihian has nothing to disclose.
Paola Sandroni, MD, PhD, FAAN (Mayo Clinic) Dr. Sandroni has nothing to disclose.
Eduardo E. Benarroch, MD, FAAN (Mayo Clinic) Dr. Benarroch has nothing to disclose.
James H. Bower, MD, MSc, FAAN (Mayo Clinic) The institution of Dr. Bower has received research support from Abbvie.
Phillip A. Low, MD, FAAN (Mayo Clinic) Dr. Low has nothing to disclose.
Wolfgang Singer, MD, FAAN (Mayo Clinic) Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. The institution of Dr. Singer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Yoda. Dr. Singer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. Dr. Singer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ferrer. The institution of Dr. Singer has received research support from NIH. The institution of Dr. Singer has received research support from FDA. The institution of Dr. Singer has received research support from Michael J. Fox Foundation. Dr. Singer has received intellectual property interests from a discovery or technology relating to health care.
Elizabeth A. Coon, MD, FAAN (Mayo Clinic) Dr. Coon has received publishing royalties from a publication relating to health care. Dr. Coon has a non-compensated relationship as a Non-Voting Member of the Board of Directors with UCNS that is relevant to AAN interests or activities.